Navigation Links
Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
Date:4/24/2013

SUMMIT, N.J., April 24, 2013 /PRNewswire/ -- As leaders across business, policy and academia gathered at the recent World Health Care Congress (WHCC) to discuss ways to improve the quality and cost of healthcare, experts in treatment adherence identified a common theme: a patient-centric adherence strategy will be critical to achieving success.

"Healthcare reform is placing greater pressure for cost-efficiencies in the delivery of patient care and, as such, healthcare companies need to integrate treatment adherence strategies at the center of their programs," said Lina Eliasson , Ph.D., lead clinical strategist with Atlantis Healthcare, a sponsor of WHCC.  "Many exciting programs presented by industry leaders assumed a high degree of patient adherence – but in reality, treatment nonadherence is an enormous problem that can undermine the successful outcomes of any plan."

A report from the New England Healthcare Institute estimates that nonadherence to medication contributes $290 billion annually in unnecessary costs – about 13% of the total US healthcare expenditure. The report also notes that adherence rates are lower among patients with chronic conditions (i.e., diabetes, heart disease) than among those with acute conditions.

The most popular topics during the three-day WHCC conference centered on improving cost, quality and access to patient care:

  • Impact of the Patient Protection and Affordable Care Act
  • Role of integrated care and its effect on bundled care packages
  • Tele-health and implications for providers and payors
  • Employee wellness/assistance programs

While all talks referenced adherence, the topic of medication adherence was not featured as a headline item on the agenda, reinforcing the need for greater visibility.

Dr. Eliasson believes treatment adherence will emerge as an essential component in delivering positive outcomes across these areas and beyond.  "An effective strategy that motivates patients to follow prescribed treatment or a recommended health plan will decrease medication waste and overall healthcare cost, lower readmissions, and improve patient outcomes."

Understanding Intentional Nonadherence 
According to Dr. Eliasson, healthcare companies also need to have a greater awareness of the role of intentional nonadherence within the patient population. Studies show the majority of patients who don't follow their treatments are doing so on purpose – they may not believe the treatments work or that the benefits outweigh the side effects. 

"These patients need more than reminder calls and pillbox alarms," said Dr. Eliasson. "They need specific strategies and education to change their beliefs about their illness – and to motivate them to manage their health for the long term."

For more information on treatment adherence in healthcare, visit www.atlantishealthcare.com.

To learn about the World Health Care Congress, visit www.worldhealthcarecongress.com

About Atlantis Healthcare 
Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide.  Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders. www.atlantishealthcare.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.  
Lina Eliasson 
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=112389


'/>"/>
SOURCE Atlantis Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):